New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2013
05:55 EDTTA, TA, OPTT, OPTT, KIRK, KIRK, GLP, GLP, DYN, DYN, DSX, DSX, CORE, CORE, CBRX, CBRX, CBLI, CBLI, ADES, ADESCompanies reporting Before the Market Open on Thursday, March 14
Notable companies reporting before the opening bell on Thursday include ADA-ES (ADES), Cleveland BioLabs (CBLI), Columbia Laboratories (CBRX), Core-Mark Holding (CORE), Diana Shipping (DSX), Dynegy (DYN), Global Partners (GLP), Kirkland's (KIRK), Ocean Power Technologies (OPTT), and TravelCenters of America (TA).
Check below for free stories on ADES;CBLI;CBRX;CORE;DSX;DYN;GLP;KIRK;OPTT;TA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2014
09:00 EDTADESAdvanced Emissions falls 11.9%
Advanced Emissions is down 11.9%, or $2.85, to $21.00
08:32 EDTGLPGlobal Partners announces pipeline connection agreement
Subscribe for More Information
07:26 EDTADESAdvanced Emissions finds material weakness related to internal controls
Subscribe for More Information
April 23, 2014
08:32 EDTGLPGlobal Partners increases quarterly dividend 2% to 62.5c per share
Subscribe for More Information
April 21, 2014
10:01 EDTDYNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:07 EDTDYNDynegy upgraded to Buy from Neutral at UBS
Subscribe for More Information
April 16, 2014
08:12 EDTCBLICleveland BioLabs announces successful completion of Phase 1 study of CBL0102
Cleveland BioLabs announced the achievement of all objectives in a Phase 1 clinical trial of CBL0102, or quinacrine, an orally administered small molecule. The study was performed in patients with advanced cancers for which no standard care exists or which had become resistant to conventional therapies. All patients had tumors involving the liver. CBL0102 is being developed by Incuron, a joint venture between Bioprocess Capital Ventures and Cleveland BioLabs. The primary objective of the study was to evaluate for a maximum tolerated dose and dose-limiting toxicities of CBL0102 in patients with advanced cancers. Secondary objectives were to characterize the drug's safety and to profile its pharmacokinetics. The study also assessed for preliminary evidence of CBL0102 antitumor activity. In particular, the study was designed to explore potential effects related to CBL0102's high relative biodistribution into the liver and therefore included only patients with primary or metastatic liver cancers. Patients were enrolled to receive sequentially higher starting doses of CBL0102 in seven cohorts. Study participants were treated with CBL0102 given orally daily. Patients could continue therapy for eight weeks, or longer if they appeared to be benefiting from therapy.
April 15, 2014
05:59 EDTDSXScorpio, Diana Shipping trade well below NAV, says Deutsche Bank
Deutsche Bank says shares of Scorpio Bulkers (SALT) and Diana Shipping (DSX) are trading well below their net asset values following the recent pullback in the names. Deutsche points out that new and secondhand dry bulk asset prices have increased materially since the end of 2013. It reiterates Buy ratings on both stocks.
April 14, 2014
10:02 EDTOPTTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:16 EDTOPTTOcean Power initiated with a Buy at H.C. Wainwright
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use